

OBSERVATIONS

High Prevalence of Immunounreactive Albumin in Urine From Diabetic Patients With a Low Glomerular Filtration Rate and Normoalbuminuria

Diabetic patients have been shown to excrete increased quantities of albumin, which is undetectable by conventional albumin antibodies (immunounreactive) using high-performance liquid chromatography (HPLC) (1). Furthermore, the lead time for the development of microalbuminuria (albumin excretion rate [AER] $>20 \mu\text{g}/\text{min}$) measured by HPLC has been shown to occur 3.9 and 2.4 years earlier than that determined by radioimmunoassay (RIA) for type 1 and type 2 diabetic patients, respectively (2). This study not only identified that progression from normo- to microalbuminuria is associated with an increase in urinary immunounreactive albumin, but also raises the possibility that measurement of total albumin (immunoreactive plus immunounreactive) may allow earlier detection of progression to kidney disease.

The aim of this study was to determine whether a group of type 2 diabetic patients with a low glomerular filtration rate (GFR) of $<60 \text{ ml} \cdot \text{min}^{-1} \cdot 1.73 \text{ m}^{-2}$, as measured by a single-injection isotopic technique using $^{99\text{m}}\text{Tc-DTPA}$ (3), and normoalbuminuria, as measured by RIA, excrete increased quantities of immunounreactive albumin. Total albumin was measured by HPLC analysis (1,2), and immunoreactive albumin was measured by RIA on two to three consecutive urine samples collected from 38 type 2 diabetic patients attending the Austin & Repatriation Medical Centre, Victoria, Australia. Patients who had recurrent urinary tract infections or hematuria, known nondiabetic renal disease, or severe intercurrent illness, such as a malignancy or symptomatic cardiac failure, were excluded from the study.

The major finding of this study is that 24% (9 of 38) of patients had an AER >20

$\mu\text{g}/\text{min}$ and 37% (14 of 38) of patients had an AER $>15 \mu\text{g}/\text{min}$, as measured by HPLC, in comparison with RIA analysis, which detected 0% (0 of 38) of patients with an AER $>20 \mu\text{g}/\text{min}$ and 13% (5 of 38) of patients with an AER $>15 \mu\text{g}/\text{min}$. There was no significant difference between HPLC and RIA analysis of albumin in urine from nondiabetic subjects (1). These results identify that type 2 diabetic patients with a GFR $<60 \text{ ml} \cdot \text{min}^{-1} \cdot 1.73 \text{ m}^{-2}$, and therefore presumably some form of kidney dysfunction, have an increased prevalence of urinary immunounreactive albumin. The possible pathogenesis of increased urinary immunounreactive albumin in these patients is limited given the absence of renal ultrastructural data. In fact, there is a paucity of information available regarding the renal morphology of normoalbuminuric patients with type 2 diabetes, regardless of their GFR. Nevertheless, the discrepancy between the HPLC and immunochemical assays demonstrates that conventional albumin assays may provide a relatively late diagnosis of incipient kidney disease at a threshold of $20 \mu\text{g}/\text{min}$.

The combination of impaired renal function and normoalbuminuria in patients with diabetes was first highlighted by Lane et al. (4). For healthy nondiabetic individuals, the rate of decline in GFR with age has been reported to range from 0.6 to $1.0 \text{ ml} \cdot \text{min}^{-1} \cdot 1.73 \text{ m}^{-2} \cdot \text{year}^{-1}$ (5). We have previously shown that the rate of decline in renal function for normoalbuminuric type 2 diabetic patients is $-5.5 \pm 1.0 \text{ ml} \cdot \text{min}^{-1} \cdot 1.73 \text{ m}^{-2} \cdot \text{year}^{-1}$, which is clearly greater than that related to aging alone (6). It should also be noted that the rate of decline in patients who had a GFR of $<60 \text{ ml} \cdot \text{min}^{-1} \cdot 1.73 \text{ m}^{-2}$ and normoalbuminuria was similar to that observed for micro- and macroalbuminuric patients (6).

In summary, this study demonstrates that urine from diabetic patients with a low GFR contains a high prevalence of immunounreactive albumin as measured by HPLC. This indicates that HPLC analysis of albumin components in the urine may provide a better indication of kidney dysfunction than the conventional immunoassays currently available.

TANYA M. OSICKA, PHD¹

RICHARD J. MACISAAC, PHD, FRACP^{2,3}

GEORGE JERUMS, MD, FRACP^{2,3}

WAYNE D. COMPER, DSC, PHD¹

From the ¹Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia; the ²Endocrinology Unit, Austin Health, Heidelberg, Victoria, Australia; and the ³Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.

Address correspondence to Dr. Wayne D. Comper, Department of Biochemistry & Molecular Biology, Monash University, Wellington Road, Clayton, Victoria, Australia 3800. E-mail: wayne.comper@med.monash.edu.au.

© 2004 by the American Diabetes Association.

References

- Comper WD, Osicka TM, Jerums G: High prevalence of immuno-unreactive intact albumin in the urine of diabetic patients. *Am J Kidney Dis* 41:336–342, 2003
- Comper WD, Osicka TM, Clark M, MacIsaac RJ, Jerums G: Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. *Kidney Int* 65:1850–1855, 2004
- Houlihan C, Jenkins M, Osicka T, Scott A, Parkin D, Jerums G: A comparison of the plasma disappearance of iohexol and $^{99\text{m}}\text{Tc-DTPA}$ for the measurement of glomerular filtration rate (GFR) in diabetes. *Aust N Z J Med* 29:693–700, 1999
- Lane PH, Steffes MW, Mauer SM: Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. *Diabetes* 41:581–586, 1992
- Clase CM, Garg AX, Kiberd BA: Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). *J Am Soc Nephrol* 13:1338–1349, 2002
- MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Nonalbuminuric renal insufficiency in type 2 diabetes. *Diabetes Care* 27:195–200, 2004

Understanding the Associations Between Statewide Diabetes Prevalence and Air Pollution Emissions

In a recent letter in *Diabetes Care*, Lockwood (1) presented a statistically significant correlation between statewide diabetes prevalence and statewide total air pollution emissions reported in the Environmental Protection Agency's (EPA) toxic release inventory (TRI) database

($r = 0.54, P < 0.0001$). Lockwood noted that such a correlation does not necessarily result from a causal relationship, but called for further research into understanding the association between air pollution and diabetes. In response, Nicolich (2) took issue with Lockwood's use of statewide data. To demonstrate that correlations based on statewide data may not show causal relationships, Nicolich presented four highly statistically significant correlations between statewide diabetes prevalence and factors that would not be expected to be causal factors in diabetes: latitude of the state capital, longitude of the state capital, state population, and numerical position of the state name on an alphabetized list. Nicolich stated that relationships should be based on individual-level data, rather than statewide data, and on the existence of a plausible mechanism. Lockwood's response (3) pointed out a previous association between Nicolich and ExxonMobil but did not address Nicolich's claim that statewide data are inherently prone to nonsensical correlations.

The highly significant correlations pointed out by both Lockwood and Nicolich are puzzling. There should be some explanation for these correlations, though as both authors note, this explanation need not be causal in nature. To investigate the issue further, the calculations of Lockwood and Nicolich were repeated using data available on the internet (<http://www.epa.gov/tri>, <http://www.census.gov>, and <http://apps.nccd.cdc.gov/brfss>). The Pearson correlation coefficient calculated between log diabetes prevalence and log TRI air emissions matched the value reported by Lockwood ($r = 0.54, P < 0.0001$). The correlation between log population and log diabetes prevalence ($r = 0.48, P < 0.001$) also closely matched the value reported by Nicolich. However, the correlation of diabetes prevalence and state alphabetic rank was nonsignificant ($r = -0.017, P = 0.904$), in contrast to the results reported by Nicolich ($r = 0.49, P < 0.001$). Log transformations of either or both variables did not produce a statistically significant result.

The potential role of confounding in producing these correlations was examined using a multivariate regression approach. Statewide diabetes prevalence was regressed on both state population and TRI emissions because these factors

Table 1—Linear regression coefficients

Variable	Standardized coefficient	t	P
ln TRI emissions	0.235	1.297	0.201
ln population	0.079	0.387	0.701
ln percent white	-0.125	-0.919	0.363
ln percent African American	0.487	3.417	0.001
ln percent Latino	-0.142	-0.940	0.352

The natural logarithm of the state prevalence of diabetes is the dependent variable.

had been shown to be significant in the bivariate analysis. In addition, the proportions of the state population in each of three ethnic groups (African American, Latino, and white) were included in the regression because ethnicity is known to influence diabetes prevalence. All variables were log transformed since this was observed to produce roughly normally distributed residuals.

The results (Table 1) indicate that only the association between statewide diabetes prevalence and proportion of African-American population is statistically significant. The bivariate correlations noted by Lockwood and Nicolich appear to result from partial confounding with this factor. African Americans have historically migrated to large industrial states, such as New York, Michigan, Louisiana, and Texas, that would be expected to have both high populations and high TRI air emissions. In contrast, rural northern states, such as Vermont, North Dakota, and Idaho, have low populations, low TRI emissions, and low proportions of African Americans. The negative correlations with latitude and longitude reported by Nicolich appear to result from higher African-American populations in the southeastern states.

This does not rule out air pollution as a causal factor in diabetes. However, the analysis of state-level emissions data is unlikely to yield much insight into this issue given the lack of contaminant-specific exposure information, the small variation in the statewide prevalence that would be expected from environmental factors, and the many potentially confounding factors. Further research into the causes of diabetes is certainly desirable (1), and promising avenues of research (2) include individual-level and mechanistic studies (4–8).

Although the analysis of state-level data would not be expected to be a pow-

erful tool to understand individual-level risk factors, it may be a worthwhile enterprise for other reasons. Understanding regional variations and their underlying causes may help to focus and prioritize efforts to improve health outcomes. In this particular case, the explanatory power of ethnicity is striking and may provide motivation to efforts to assist African Americans with both the prevention and treatment of diabetes.

ELIA B. MARQUEZ, MS
BENJAMIN R. DIAZ, MS
PATRICK L. GURIAN, PHD

From the Environmental Science and Engineering Program, University of Texas at El Paso, El Paso, Texas.

Address correspondence to Dr. Patrick Gurian, Department of Civil Engineering, University of Texas at El Paso, El Paso, TX 79968. E-mail: pgurian@utep.edu.

© 2004 by the American Diabetes Association.

References

1. Lockwood AH: Diabetes and air pollution (Letter). *Diabetes Care* 25:1487–1488, 2002
2. Nicolich MJ: Diabetes and the state capital (Letter). *Diabetes Care* 25:2367, 2002
3. Lockwood AH: Response to Nicolich (Letter). *Diabetes Care* 25:2367–2368, 2002
4. Henriksen GL, Ketchum NS, Michalek JE, Swaby JA: Serum dioxin and diabetes mellitus in veterans of Operation Ranch Hand. *Epidemiology* 8:252–258, 1997
5. Michalek JE, Akhtar FZ, Kiel JL: Serum dioxin, insulin, fasting glucose, and sex hormone-binding globulin in veterans of Operation Ranch Hand. *J Clin Endocrinol Metab* 84:1540–1543, 1999
6. Calvert GM, Sweeney MH, Deddens J, Wall DK: Evaluation of diabetes mellitus, serum glucose, and thyroid function among United States workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Occup Environ Med* 56:270–276, 1999
7. Roegner RH, Grubbs WD, Lustik MB, Brockman AS, Henderson SC: *Air Force*

Health Study: An Epidemiologic Investigation of Health Effects in Air Force Personnel Following Exposure to Herbicides. McLean, VA, Science Applications International Corporation, 1991

8. *Veterans and Agent Orange: Herbicide/Dioxin Exposure and Type 2 Diabetes: Committee to Review the Evidence Regarding the Link Between Exposure to Agent Orange and Diabetes.* Washington, D.C., Division of Health Promotion and Disease Prevention, Institute of Medicine, National Academy Press, 2000

Intrinsic Motivation and Glycemic Control in Adolescents with Type 1 Diabetes

Treatment for type 1 diabetes is often difficult for adolescents because of the multiple daily tasks required for successful management. Hence, adolescents who are more intrinsically motivated to manage their health might be more persistent with their diabetes care and consequently be in better glycemic control. We therefore examined the proportion of variance that intrinsic motivation contributed to HbA_{1c} in 43 adolescents diagnosed with type 1 diabetes relative to other disease-related and psychosocial factors that have been linked to glycemic control in cross-sectional research.

After receiving approval from the institutional review board, we recruited adolescents with a mean age of 14.14 ± 1.73 years from a university-affiliated diabetes clinic to participate in the study. All of the participants had been diagnosed with diabetes for a minimum of 1 year (M = 5.85 ± 4.53 years), and none were on an insulin pump. The sample consisted mostly of girls (65%); 74% were Caucasian, and 26% were African American. The mean family income was in the \$30,000–45,000 range. The adolescents completed standardized measures of intrinsic/extrinsic motivation (Health Self-Determinism Index for Children), self-efficacy (Self-Efficacy for Diabetes Scale), family conflict (Family Environment Scale), diabetes-specific family behaviors (Diabetes Family Behavior Scale), and adherence to their diabetes regimen (Diabetes Regimen Adherence Questionnaire) while waiting for their medical appointment with the physician. Their parents completed a screening measure of behav-

ioral adjustment on the adolescent (Pediatric Symptom Checklist) and a general demographic questionnaire.

Bivariate correlations revealed that adolescents who were more intrinsically motivated to manage their health were more likely to report adhering to their treatment ($r = 0.38, P < 0.05$) but were also more likely to be in poorer metabolic control, as measured by HbA_{1c}, at the time of testing ($r = 0.43, P < 0.05$). The relation between intrinsic motivation and poor glycemic control was unexpected, but is consistent with research (1) suggesting that adolescents who are primarily responsible for their diabetes care tend to be in poor metabolic control. Family conflict was also found to be related to poor adherence ($r = -0.38, P < 0.05$) and to being in poor glycemic control at the time of testing ($r = 0.35, P < 0.05$). But intrinsic motivation was the only psychosocial variable that was related to HbA_{1c} 4 months later ($r = 0.41, P < 0.05$). The proportion of variance that intrinsic motivation contributed to future glycemic control, however, was not significant after controlling for baseline HbA_{1c} in hierarchical regression analyses. Given that baseline HbA_{1c} was highly correlated with follow-up HbA_{1c} ($r = 0.78, P < 0.0001$), further research on intrinsic motivation is worth pursuing with larger samples.

Although we observed significant relations between intrinsic motivation and both adherence and HbA_{1c}, we did not observe a significant relation between adherence and HbA_{1c} at baseline ($r = -0.10$) or at follow-up ($r = -0.06$), which is similar to reports in the literature (2). The present findings suggest that adolescents who are intrinsically motivated could be at risk for poor glycemic control because they are more likely to rely on their own internal cues and judgment for managing their health. Adolescents may lack the experience and objectivity to make medically sound judgments. Thus, frequent consultation with parents and medical staff may be recommended instead of encouraging adolescents to assume more personal responsibility for their diabetes care. This recommendation contradicts the popular practice of encouraging adolescents to manage their diabetes care autonomously, but may be warranted until they can successfully manage their diabetes independently.

LEILANI GREENING, PHD^{1,2}
 LAURA STOPPELBEIN, PHD²
 GEORGE MOLL, MD, PHD³
 NICOLE PALARDY, PHD¹
 MATTHEW HOCKING, BS¹

From the ¹Department of Psychology, University of Alabama, Tuscaloosa, Alabama; the ²Department of Psychiatry, University of Mississippi Medical Center, Jackson, Mississippi; and the ³Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi.

Address correspondence to L. Greening, Box 870348, University of Alabama, Tuscaloosa, AL 35487-0348. E-mail: green@bama.ua.edu.

© 2004 by the American Diabetes Association.

References

1. Florian V, Elad D: The impact of mothers' sense of empowerment on the metabolic control of their children with juvenile diabetes. *J Pediatr Psychol* 23:239–247, 1998
2. Johnson SB: Insulin dependent diabetes mellitus in childhood. In *Handbook of Pediatric Psychology*. 2nd ed. Roberts MC, Ed. New York, Guilford Press, 1995, p. 263–285

The Metabolic Syndrome in Inuit

Inuit have been considered to have a lower prevalence of diabetes and age-adjusted mortality from cardiovascular disease than the general population (1,2). This observation has prompted investigation of both traditional and newer cardiovascular risk factors. A new risk cluster called the metabolic syndrome, defined as three or more of 1) fasting glucose ≥6.1 mmol/l; 2) blood pressure ≥130/85 mmHg; 3) triglycerides ≥1.69 mmol/l; 4) HDL cholesterol <1.04 mmol/l in men or <1.29 in women; and 5) waist circumference >102 cm in men or >88 cm in women (3), has not been evaluated in the Inuit. We thus determined the prevalence of the metabolic syndrome among 168 Inuit (48.2% women) and 53 Caucasian control subjects (38.5% women) who were residents in the arctic and had participated in a cardiovascular survey in 1989–1991 (2). Using the 2001 criteria, we found that Inuit had a lower prevalence of the metabolic syndrome (13.1%) compared with both regional Caucasian control subjects (20.8%) and Caucasian subjects from the contemporaneous 1988–1994 National Health and Nutrition Examination Survey (NHANES) III

only when a more severe insulin secretory defect is present. Second, as discussed by Roder et al. (5), this ratio is associated with insulin sensitivity in a group of subjects covering a broad range of insulin resistance. Thus, because in the article by Bacha et al. the proinsulin-to-insulin ratio was adjusted for BMI but not for insulin sensitivity, it remains unclear whether the relationship with adiponectin simply reflects insulin sensitivity.

Based on the findings in the study by Bacha et al., we investigated whether plasma adiponectin is associated with parameters of insulin secretory function in our database from the Tübingen Family Study. A total of 685 normal glucose tolerant subjects (aged 36 ± 0.4 years [mean \pm SE]) were included and underwent a 75-g oral glucose tolerance test (OGTT). We measured insulin and proinsulin and determined the fasting proinsulin-to-insulin ratio. The 30-min C-peptide plasma concentrations during the OGTT and the first-phase insulin secretory index (ISI) proposed by Stumvoll et al. (6) were used as an estimate of β -cell function. Insulin sensitivity was calculated as proposed by Matsuda et al. (7). In multiple linear regression models, neither proinsulin-to-insulin ratio ($r = 0.03$, $P = 0.46$) nor 30-min C-peptide plasma concentrations ($r = 0.01$, $P = 0.79$) or ISI ($r = 0.01$, $P = 0.80$) during the OGTT were associated with fasting plasma adiponectin concentrations after adjustment for age, sex, percentage body fat, and insulin sensitivity. These findings argue against an association of plasma adiponectin concentrations with β -cell function.

NORBERT STEFAN, MD
MICHAEL STUMVOLL, MD
HANS-ULRICH HÄRING, MD
ANDREAS FRITSCHE, MD

From the Department of Internal Medicine, Division of Endocrinology, Metabolism and Pathobiochemistry, University of Tübingen, Tübingen, Germany.

Address correspondence to Norbert Stefan, MD, Department of Internal Medicine, University of Tübingen, Otfried-Müller Str. 10, 72076 Tübingen, Germany. E-mail: norbert.stefan@med.uni-tuebingen.de.

© 2004 by the American Diabetes Association.

References

1. Bacha F, Saad R, Gungor N, Arslanian SA: Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity and

β -cell function. *Diabetes Care* 27:547–552, 2004

2. Kharroubi I, Rasschaert J, Eizirik DL, Cnop M: Expression of adiponectin receptors in pancreatic beta cells. *Biochem Biophys Res Commun* 31:1118–1122, 2003
3. Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J: Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. *Diabetologia* 47:249–258, 2004
4. Roder ME, Porte D Jr, Schwartz RS, Kahn SE: Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 83:604–608, 1998
5. Roder ME, Schwartz RS, Prigeon RL, Kahn SE: Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. *J Clin Endocrinol Metab* 85:2275–2280, 2000
6. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. *Diabetes Care* 23:295–301, 2000
7. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 22:1462–1470, 1999

Adiponectin in Youth

Response to Stefan et al.

We appreciate the comments of Stefan et al. (1) in this issue of *Diabetes Care* regarding adiponectin in youth. We are excited to have received the opinion of investigators in internal medicine, since traditionally pediatric investigations seldom cross the boundaries to adult medicine. The changing face of childhood diabetes might be playing a role (2). We offer the following responses.

1) Our study demonstrated associations and correlations between adiponectin and proinsulin and the proinsulin-to-insulin ratio. We never implied that a direct effect of adiponectin on insulin secretory function exists. However, as recommended by Stefan et al., we investigated the relationship between the proinsulin-to-insulin ratio and adiponectin after adjusting for insulin sensitivity per metabolically active fat-free mass. The

partial correlation coefficient of adiponectin to the proinsulin-to-insulin ratio after controlling for insulin sensitivity was $r = -0.24$, two-tailed $P = 0.12$, and one-tailed $P = 0.06$. Furthermore, in a multiple regression analysis with proinsulin-to-insulin ratio as the dependent variable and adiponectin and insulin sensitivity as the independent variables, adiponectin ($P = 0.007$) and not insulin sensitivity ($P = 0.60$) was the significant independent correlate of the proinsulin-to-insulin ratio ($R^2 = 0.168$, $P = 0.02$ with adiponectin and insulin sensitivity in the formula; $R^2 = 0.162$, $P = 0.007$ with only adiponectin in the formula). Also, in an effort to determine if adiponectin is related to an index of glucose homeostasis, we evaluated the correlation of adiponectin with the glucose disposition index (product of insulin sensitivity \times first-phase insulin secretion), which revealed that $r = 0.35$ and $P = 0.013$.

2) The observation by Roder et al. (3) that the association between the proinsulin-to-insulin ratio and acute insulin response was only present in diabetic adults and not in nondiabetic subjects is contrary to our findings in healthy adolescents. Extrapolating observations from 60-year-old subjects to adolescents may not be justified, especially taking into consideration the uniqueness of puberty-related changes in insulin sensitivity and secretion (2,4). Analysis of our unpublished data demonstrates that first-phase insulin secretion during a hyperglycemic clamp correlates positively with proinsulin ($r = 0.43$, $P = 0.04$) and the proinsulin-to-insulin ratio ($r = 0.50$, $P = 0.01$) in normal-weight adolescents ($n = 23$) with no correlations in obese adolescents ($n = 26$). Thus, in normal adolescents, the puberty-related increase in insulin secretion may also be accompanied by increased proinsulin secretion, whereas in obese adolescents, this relationship may disappear due to variable degrees of β -cell compensation.

In summary, despite the wealth of data in adults with respect to insulin sensitivity and secretion, gradually accumulating data in pediatrics would suggest that developmental differences in these parameters are distinguishing features of youth. At the moment, our data in pediatrics remain supportive of an important relationship between adiponectin and measures of β -cell function.

FIDA BACHA, MD

ROLA SAAD, MD
 NESLIHAN GUNGOR, MD
 SILVA A. ARSLANIAN, MD

From the Division of Pediatric Endocrinology, Metabolism and Diabetes Mellitus, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.

Address correspondence to Silva A. Arslanian, MD, Division of Endocrinology, Children's Hospital of Pittsburgh, 3705 Fifth Ave. at DeSoto Street, Pittsburgh, PA 15213. E-mail: silva.arslanian@chp.edu.

© 2004 by the American Diabetes Association.

Acknowledgments—This work was supported by U.S. Public Health Service Grants Ro1 HD27503, K24 HD01357, and MO1-RR00084, the General Clinical Research Center, and Eli-Lilly.

.....
References

1. Stefan N, Stumvoll M, Häring H, Fritsche A: Adiponectin in youth (Letter). *Diabetes Care* 27:1519–1520, 2004
2. Arslanian SA: Insulin resistance and insulin secretion in childhood and adolescence: their role in type 2 diabetes in youth. In *Type 2 Diabetes in Childhood and Adolescence*. Silink M, Kida K, Rosenbloom A, Eds. London, Martin Dunitz Publishing, 2003, p. 93–116
3. Roder MF, Schwartz RS, Prigeon RL, Kahn SF: Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels. *J Clin Endocrinol Metab* 85:2275–2280, 2000
4. Arslanian SA, Kalhan SC: Correlations between fatty acid and glucose metabolism: potential explanation of insulin resistance of puberty. *Diabetes* 43:908–914, 1994

Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria

Response to Andersen, Bröchner-Mortensen, and Parving

We read with great interest the article by Andersen, Bröchner-Mortensen, and Parving (1) about the effects of long-term treatment

with irbesartan on kidney function in a subgroup of the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study (IRMA)-2 trial (2). In this population, the authors did not find a significant difference between irbesartan and placebo administration with respect to the change in the glomerular filtration rate (GFR). In the RESULTS section of the article, the authors report that a similar change in the GFR occurred in all study groups during the first 3 months (loss of GFR: 1.0 to 1.3 ml · min⁻¹ · 1.73 m⁻² · month⁻¹) as well as for the rest of the follow-up period (0.3 to 0.4 ml · min⁻¹ · 1.73 m⁻² · month⁻¹). However, in Fig. 2, the slope of GFR for placebo is exactly the same during the entire duration of the study, including the first 3 months, 0.3 ml · min⁻¹ · 1.73 m⁻² · month⁻¹, which is obviously contradictory to the aforementioned numbers in the RESULTS section of the article (1). Therefore, the loss of GFR may be more pronounced in patients treated with irbesartan than in those treated with placebo. In fact, when GFR values at the beginning of the study are compared with the final values at the end of the withdrawal period after 25 months (Fig. 2), there seems to be no loss of GFR in the placebo group at all, whereas GFR declined by about 10 and 6 ml/min in the 150- and 300-mg irbesartan groups, respectively.

THOMAS KAISER,^{1,2}
 CHRISTIANE FLORACK,¹
 PETER T. SAWICKI, MD, PHD^{1,2}

From ¹DiEM, Institute for Evidence-Based Medicine, Cologne, Germany; and the ²Department of Internal Medicine, St. Franziskus Hospital, Cologne, Germany.

Address correspondence to T. Kaiser, DiEM, Institute for Evidence-Based Medicine, Venloer Str. 301-303, D-50823 Cologne, Germany. E-mail: t.kaiser@di-em.de.

© 2004 by the American Diabetes Association.

.....
References

1. Andersen S, Bröchner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. *Diabetes Care* 26: 3296–3302, 2003
2. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345: 870–878, 2001

Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria

Response to Kaiser, Florack, and Sawicki

We thank Kaiser, Florack, and Sawicki (1) for their interest in our article (2). The glomerular filtration rate (GFR) values in Fig. 2 represent the mean values of measurements carried out at the specified visits. However, the rates of decline in GFR cannot be correctly estimated from Fig. 2, but are instead calculated from paired observations of changes in GFR and specified in the RESULTS section. GFR values at baseline were available from 42, 38, and 39 patients from the placebo, irbesartan 150-mg, and irbesartan 300-mg groups, respectively, whereas paired observations of changes in GFR during the initial 3 months of the study were accessible from 37, 37, and 34 patients in the placebo, irbesartan 150-mg, and irbesartan 300-mg groups, respectively. Rates of decline in GFR during the initial 3-month period were 1.3 ± 0.7, 1.2 ± 0.7, and 1.0 ± 0.8 ml · min⁻¹ · month⁻¹, as specified in the RESULTS section.

According to Fig. 2, GFR was unchanged from baseline to the end of the study after withdrawal of antihypertensive medication (24 + 1 month) in the placebo group compared with a decline in GFR of 10 ml/min in the irbesartan 150-mg group and 5 ml/min in the irbesartan 300-mg group. However, changes in GFR from baseline to the end of the study cannot be precisely evaluated from Fig. 2 due to fewer patients at the end of the study. By paired comparisons of changes in GFR from baseline to the end of the study after withdrawal of antihypertensive medication (24 + 1 month), rates of decline in GFR were 0.3 ± 0.1, 0.5 ± 0.1, and 0.3 ± 0.1 ml · min⁻¹ · month⁻¹ in the placebo (23 patients), irbesartan 150-mg (17 patients), and

Downloaded from <http://diabetesjournals.org/care/article-pdf/27/6/1520/646018/1520.pdf> by guest on 01 December 2022

irbesartan 300-mg (19 patients) groups, respectively ($P = \text{NS}$).

In conclusion, rates of decline in GFR during the study were similar in the placebo and irbesartan-treated groups, as specified in the RESULTS section of our article (2).

STEEN ANDERSEN, MD¹

JENS BRÖCHNER-MORTENSEN, MD, DMSC²

HANS-HENRIK PARVING, MD, DMSC^{1,3}

From the ¹Steno Diabetes Center, Gentofte, Denmark; the ²Department of Clinical Physiology, Aalborg Sygehus, Aalborg, Denmark; and the ³Faculty of Health Science, University of Aarhus, Aarhus, Denmark.

Address correspondence to Steen Andersen, MD, Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: stan@steno.dk.

S.A. has received research funding from Merck. H.-H.P. holds stock in Novo Nordisk, has received honoraria and consulting fees from Merck and Sanofi-Synthelabo, and has received grants from Merck, Astra, and Sanofi-Synthelabo.

© 2004 by the American Diabetes Association.



References

1. Kaiser T, Florack C, Sawicki PT: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria (Letter). *Diabetes Care* 27:1521, 2004
2. Andersen S, Bröchner-Mortensen J, Parving HH: Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. *Diabetes Care* 26:3296–3302, 2003